Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metast...
Breast Cancer Research - Following the PALOMA-3 study results, the combination of palbociclib, a CDK4/6 inhibitor, with fulvestrant, a selective estrogen receptor degrader, has become a standard...
link.springer.com